Back to results
US 10,328,159 B2Granted
Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
AssigneeEngenic Molecular Delivery Pty Ltd.
InventorsHimanshu Brahmbhatt, Jennifer MacDiarmid
Life of this patent
Estimating the term…
Abstract
Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
Claims12
A composition comprising an intact bacterially derived minicell, wherein:
- (a) the minicell encloses at least about 500,000 molecules of a fluorescent small molecule drug, and
- (b) the fluorescent small molecule drug is not doxorubicin, irinotecan, bisantrene, topotecan, epirubicin, daunorubicin, mitoxantrone, L-alanine, N-[(2′,7′-difluoro-3′,6′-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9′-[9H]xanthen]-5-yl)carbonyl]-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-9-[(2R,3S)-3-(benzoylamino)-2-hydroxy-1-oxo-3-phenylpropoxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy, or vinblastine conjugated to 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene.
A composition comprising an intact and nonliving bacterial vesicle that encloses at least about 500,000 copies a compound of formula D-L-F or a salt thereof, wherein D is the residue of a small molecule drug, L is a linker, and F is a fluorescent moiety, wherein the linker:
- (a) has a half-life of between about 6 hours and about 24 hours;
- and/or
- (b) is degraded in the endosome of a mammalian cell.
Dependencies are inferred from the claim text.